First Wave BioPharma Inc. [FWBI] Stock trading around $4.22 per share: What’s Next?

First Wave BioPharma Inc. [NASDAQ: FWBI] closed the trading session at $4.22 on 09/06/22. The day’s price range saw the stock hit a low of $3.63, while the highest price level was $4.90. The company report on August 31, 2022 that First Wave BioPharma Announces AAPS 2022 PharmSci 360 Accepts Adrulipase Formulation Abstract.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Research involves microgranule delivery formulations for adrulipase.

First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that an abstract titled, “Formulation Development of Enterically Protected Spray Dried Dispersions of Adrulipase,” has been accepted at AAPS 2022 PharmSci 360. The conference will be held Oct. 16-19 at the Boston Convention & Exhibit Center.

The stocks have a year to date performance of -90.27 percent and weekly performance of 32.70 percent. The stock has been moved at -86.73 percent over the last six months. The stock has performed -9.13 percent around the most recent 30 days and changed -52.28 percent over the most recent 3-months.

If compared to the average trading volume of 191.91K shares, FWBI reached to a volume of 30105339 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about First Wave BioPharma Inc. [FWBI]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for FWBI shares is $25.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on FWBI stock is a recommendation set at 2.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

FWBI stock trade performance evaluation

First Wave BioPharma Inc. [FWBI] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 32.70. With this latest performance, FWBI shares dropped by -9.13% in over the last four-week period, additionally sinking by -86.73% over the last 6 months – not to mention a drop of -97.76% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for FWBI stock in for the last two-week period is set at 48.36, with the RSI for the last a single of trading hit 55.33, and the three-weeks RSI is set at 43.68 for First Wave BioPharma Inc. [FWBI]. The present Moving Average for the last 50 days of trading for this stock 5.18, while it was recorded at 3.34 for the last single week of trading, and 24.73 for the last 200 days.

First Wave BioPharma Inc. [FWBI]: An insightful look at the core fundamentals

First Wave BioPharma Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.10 and a Current Ratio set at 0.10.

First Wave BioPharma Inc. [FWBI]: Insider Ownership positions

There are presently around $0 million, or 1.30% of FWBI stock, in the hands of institutional investors. The top three institutional holders of FWBI stocks are: GEODE CAPITAL MANAGEMENT, LLC with ownership of 3,034, which is approximately 0% of the company’s market cap and around 0.40% of the total institutional ownership; BLACKROCK INC., holding 2,934 shares of the stock with an approximate value of $12000.0 in FWBI stocks shares; and BANK OF NEW YORK MELLON CORP, currently with $12000.0 in FWBI stock with ownership of nearly 0.556% of the company’s market capitalization.

Positions in First Wave BioPharma Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 7 institutional holders increased their position in First Wave BioPharma Inc. [NASDAQ:FWBI] by around 8,315 shares. Additionally, 9 investors decreased positions by around 18,805 shares, while 8 investors held positions by with 8,977 shares. The mentioned changes placed institutional holdings at 18,143 shares, according to the latest SEC report filing. FWBI stock had 4 new institutional investments in for a total of 5,743 shares, while 5 institutional investors sold positions of 17,901 shares during the same period.


Please enter your comment!
Please enter your name here